Eli Lilly VIVID-1 Study
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo and Active Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients with Moderatly to Severly Active Crohn’s Disease
CONDITION: Crohn’s Disease
Purpose of the Study
The purpose of the study is to see if the study drug Mirikizumab is safe and effective in participants with moderately to severely active Crohn’s Disease.
Who Can Participate
Participants 18 years and older diagnosed with moderate to severe Crohn’s Disease three months prior to starting this study may be eligible to participate.